Ann: New Independent Trial Data Supports Potential of Veyonda, page-17

By all means wave the pom-poms but what this announcement avoids is things like the fact the warmth study patients were older, had higher PSA, more lung and liver metastases than Lupin patients and the real gem for me, warmth median only 3 cycles Lu vs median 5 cycles Lu in lupin. So less treatment in Warmth with the lutetium. not well matched groups after all it seems

so yes I stick with my view this isn’t a valid comparison and trumpeting 71% survival improvement with Nox is pretty poor science and BS - imo.